血清血脂及载脂蛋白浓度与乳腺癌分子分型及Ki-67表达水平的相关性研究

doi:10.3969/j.issn.1006-7795.2019.02.007

首都医科大学学报 ›› 2019, Vol. 40 ›› Issue (2): 191-194.doi: 10.3969/j.issn.1006-7795.2019.02.007

• 肿瘤的免疫治疗与代谢 • 上一篇下一篇

血清血脂及载脂蛋白浓度与乳腺癌分子分型及Ki-67表达水平的相关性研究

陈妮娜, 范怡畅, 尚昆, 杨婧, 曹邦伟

首都医科大学附属北京友谊医院肿瘤中心, 北京 100050

收稿日期:2019-01-17 出版日期:2019-03-21 发布日期:2019-04-15
通讯作者: 曹邦伟 E-mail:oncology@ccmu.edu.cn
基金资助:
北京市自然科学基金（7172061），首都卫生发展科研专项（2018-2-2022），北京市医院管理局消化内科学科协同发展中心经费资助（XXT01），中国人口宣传教育中心调研推广项目（2017-A001）。

Serum lipid and apolipoprotein levels were associated to the Ki-67 and molecular classification of breast cancer

Chen Nina, Fan Yichang, Shang Kun, Yang Jing, Cao Bangwei

Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received:2019-01-17 Online:2019-03-21 Published:2019-04-15
Supported by:
This study was supported by Natural Science Foundation of Beijing (7172061), Capital Health Development Research Project (2018-2-2022), Funding for the Collaborative Development Center of the Department of Gastroenterology, Beijing Hospital Administration (XXT01),China Population Publicity and Education Center Research and Promotion Project (2017-A001).

摘要/Abstract

摘要： 目的探讨血清血脂以及载脂蛋白浓度与乳腺癌分子分型及Ki-67表达水平的关系。方法选取2012年1月至2017年5月乳腺癌术后且未行化学药物治疗（以下简称化疗）的患者143例，检测体内高密度脂蛋白胆固醇（high density lipoprotein-cholesterol，HDL-C）、低密度脂蛋白胆固醇（low density lipoprotein-cholesterol，LDL-C）、胆固醇（cholesterol，TC）和载脂蛋白B（apolipoprotein B，ApoB）、载脂蛋白A（apolipoprotein A，ApoA）及三酰甘油（triglyceride，TG）浓度，并在乳腺癌的不同分子分型中进行对比。结果 HDL-C、LDL-C、TC、ApoA及TG在不同乳腺癌亚型患者间差异具有统计学意义（P<0.05）。ApoA在不同乳腺癌亚型患者间差异无统计学意义（P>0.05）。LDL-C、TC及ApoB浓度与Ki-67表达水平呈正相关，HDL-C和Ki-67之间呈负相关，ApoB和TG及Ki-67表达无关。结论乳腺癌的分子亚型不同，其血脂代谢也有差异，同时血脂浓度与Ki-67表达相关，高浓度的TC与LDL-C以及低浓度的HDL-C提示预后不良。

关键词: 乳腺癌, 分子分型, 血脂

Abstract: Objective To investigate the relationship between serum lipid and molecular types, Ki-67 level of breast cancer. Methods Total of 143 breast cancer patients who underwent the surgery from January 2012 to May 2017 were enrolled. The level of high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), cholesterol (TC), apolipoprotein B (ApoB), apolipoprotein A (ApoA),and triglyceride (TG) were measured. The relationship between the above factors and the different molecular types of breast cancer was analyzed and discussed. Results The level of HDL-C, LDL-C, TC, ApoB and TG were significantly associated with different breast cancer subtypes (P<0.05). No significant difference of ApoA levels was observed in the different breast cancer subtypes (P>0.05). The levels of LDL-C, TC and ApoB were positively correlated with Ki-67 levels, while the levels of HDL-C was negatively correlated with Ki-67 level. However, The levels of ApoB and TG showed no relation with Ki-67 expression level. Conclusion Lipid metabolism is different in different breast cancer molecular subtypes. The serum lipid level is related to the expression level of Ki-67. High levels of TC and LDL-C and low level of HDL-C suggest poor prognosis in breast cancer.

Key words: breast cancer, molecular classification, serum lipid

中图分类号:

R737.9

陈妮娜, 范怡畅, 尚昆, 杨婧, 曹邦伟. 血清血脂及载脂蛋白浓度与乳腺癌分子分型及Ki-67表达水平的相关性研究[J]. 首都医科大学学报, 2019, 40(2): 191-194.

Chen Nina, Fan Yichang, Shang Kun, Yang Jing, Cao Bangwei. Serum lipid and apolipoprotein levels were associated to the Ki-67 and molecular classification of breast cancer[J]. Journal of Capital Medical University, 2019, 40(2): 191-194.

参考文献

[1] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
[2] Bustreo S, Osella-Abate S, Cassoni P, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation:a large case series study with a long-term follow-up[J]. Breast Cancer Res Treat, 216, 157(2):363-371.
[3] Xiang Q,Tang J, Luo Q, et al. In vitro study of anti-ER positive breast cancer effect and mechanism of 1,2,3,4-6-pentyl-O-galloyl-beta-d-glucose(PGG)[J].Biomed Pharmacother,2019,111:813-820.
[4] Goldhirsch A, Winer E P, Coates A S, et al. Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013, 24(9):2206-2223.
[5] Baek A E, Nelson E R. The contribution of cholesterol and its metabolites to the pathophysiology of breast cancer[J]. Horm Cancer, 2016, 7(4):219-228.
[6] Leignadier J, Dalenc F, Poirot M, et al. Improving the efficacy of hormone therapy in breast cancer:The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and death[J]. Biochem Pharmacol, 2017,15(144):18-28.
[7] Tie G, Yan J, Khair L, et al. Hypercholesterolemia increases colorectal cancer incidence by reducing production of NKT and gammadelta T Cells from hematopoietic stem cells[J]. Cancer Res, 2017, 77(9):2351-2362.
[8] Geva S, Lazarev I, Geffen D B, et al. Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine[J]. J Chemother, 2013, 25(3):176-180.
[9] Jeon J C, Park J, Park S, et al. Hypercholesterolemia is associated with a shorter time to castration-resistant prostate cancer in patients who have undergone androgen deprivation therapy[J]. World J Mens Health, 2016, 34(1):28-33.
[10] Simon A. Cholesterol metabolism and immunity[J]. N Engl J Med, 2014, 371(20):1933-1935.
[11] Beckwitt C H, Brufsky A, Oltvai Z N, et al. Statin drugs to reduce breast cancer recurrence and mortality[J]. Breast Cancer Res, 2018, 20(1):144.
[12] Liu B, Yi Z, Guan X, et al. The relationship between statins and breast cancer prognosis varies by statin type and exposure time:a meta-analysis[J]. Breast Cancer Res Treat, 2017, 164(1):1-11.
[13] Reiner Ž. Triglyceride-rich lipoproteins and novel targets for anti-atherosclerotic therapy[J]. Korean Circ J, 2018, 48(12):1097-1119.
[14] Kapil U, Bhadoria A S, Sareen N, et al. Total cholesterol and triglyceride levels in patients with breast cancer[J]. J Breast Cancer, 2013, 16(1):129-130.
[15] Seo S H, Kim K H, Oh S H, et al.Ki-67 labeling index as a prognostic marker in advanced stomach cancer[J].Ann Surg Treat Res,2019,96(1):27-33.
[16] 黄凌萍, 丁洁琼.乳腺浸润性导管癌组织中ER、PR、Ki-67、p53表达与超声造影特征的相关性研究[J].解放军医药杂志,2017,29(9):63-66.
[17] 马海明, 刘涛,刘晓康,等.乳腺癌组织Ki-67和HER2及PHH3表达与新辅助化疗疗效相关性分析[J].中华肿瘤防治杂志,2018,25(10):709-712.
[18] Mannell A. The role of Ki-67 in breast cancer[J]. S Afr J Surg, 2016, 54(2):10-13.

血清血脂及载脂蛋白浓度与乳腺癌分子分型及Ki-67表达水平的相关性研究

Serum lipid and apolipoprotein levels were associated to the Ki-67 and molecular classification of breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[2]	魏常胜, 骆成玉, 张树琦. 环乳晕切口联合乳腔镜腋窝淋巴结清扫在早期乳腺癌保乳手术中的应用[J]. 首都医科大学学报, 2021, 42(6): 1014-1020.
[3]	中华预防医学会妇女保健分会; 中国人体健康科技促进会妇科内分泌与生育力促进专委会. 乳腺癌患者选择性雌激素受体调节剂治疗相关子宫内膜安全管理的中国专家共识(2021版)[J]. 首都医科大学学报, 2021, 42(4): 672-677.
[4]	阮祥燕, 杨瑜, 卢丹, 杜娟, 程姣姣, 谷牧青, 李扬璐, 金凤羽, 段微, 代荫梅, 鞠蕊, 许新, MatthiasKorell, AlfredO.Mueck. 中国首例乳腺癌患者冻存卵巢组织移植成功报道及文献复习[J]. 首都医科大学学报, 2021, 42(2): 177-182.
[5]	杨阳, 康骅, 赵菁, 凌煜玮, 赵烨, 王亚军, 戎冬冬. 术前乳腺MRI对乳腺癌保乳手术切缘评估的回顾性分析[J]. 首都医科大学学报, 2020, 41(6): 943-953.
[6]	董方, 陈东, 商建峰, 方微, 滕飞, 张睿祺. 门诊消化系统疾病患者幽门螺杆菌感染状况分析[J]. 首都医科大学学报, 2020, 41(3): 372-375.
[7]	王爱婷, 鄢丹, 齐宪荣. 包载多西他赛的聚合物胶束抑制小鼠乳腺癌转移作用研究[J]. 首都医科大学学报, 2020, 41(2): 225-230.
[8]	王维, 张紫寒, 翟妍, 桑翠琴, 王淑珍. 子宫体、乳腺双原发癌的临床病理特征[J]. 首都医科大学学报, 2019, 40(6): 857-862.
[9]	张蕴显, 王雅梅, 周萍. 乳腺癌中基于开放染色质的环状RNA互作网络构建及功能分析[J]. 首都医科大学学报, 2019, 40(6): 901-910.
[10]	白向东, 郝雅婷, 张欣雪, 贺强. 脾多肽注射液联合术后化疗对三阴性乳腺癌患者临床疗效的研究[J]. 首都医科大学学报, 2019, 40(6): 911-915.
[11]	张凌燕, 阮祥燕, 蔡桂举, 谷牧青, Alfred O. Mueck. 他莫昔芬治疗转染孕激素受体膜组分1乳腺癌裸鼠模型对乳腺肿瘤组织Ki-67表达的影响[J]. 首都医科大学学报, 2019, 40(4): 533-538.
[12]	王月姣, 阮祥燕, 谷牧青, 蔡桂举, 李雪, 张凌燕, Alfred O. Mueck. 他莫昔芬治疗乳腺癌异种移植瘤裸鼠子宫病理改变[J]. 首都医科大学学报, 2019, 40(4): 539-543.
[13]	白向东, 郝雅婷, 张欣雪, 贺强. 雌激素受体阳性和阴性乳腺癌术后辅助化学药物治疗中加用脾多肽的临床免疫疗效观察[J]. 首都医科大学学报, 2019, 40(3): 443-448.
[14]	李雪, 阮祥燕, 谷牧青, 蔡桂举, 赵越, Alfred O. Meuck. 孕激素受体膜组分1促进雌孕激素诱导的乳腺癌细胞增生的研究——雌二醇与周期序贯及连续联合比较[J]. 首都医科大学学报, 2019, 40(2): 237-243.
[15]	徐泉, 刘玉洁, 潘钰, 郑秀瑗, 刘静民, 孙小花, 邹丽丽, 马丽娜, 严红松. 生物电阻抗测试频率对乳腺癌相关淋巴水肿定量评估的影响[J]. 首都医科大学学报, 2018, 39(5): 747-751.